Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 81Gastrointestinal 3Thoracic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Gynecologic 2Breast 2Head & Neck 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Radiotherapy 5Magnetic Resonance Spectroscopy 5Docetaxel 5Specimen Handling 4Gemcitabine 3Cyclophosphamide 3temsirolimus 2fludarabine 2Trastuzumab 2Temozolomide 2Sirolimus 2Radiosurgery 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Leucovorin 2Injections 2Fluorouracil 2Fluorodeoxyglucose F18 2Blood Specimen Collection 2Biopsy 2Bevacizumab 2Azacitidine 2vandetanib 1ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × abiraterone × CNS × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡